Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01496313 · ClinicalTrials.gov registry record · Phase 4
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
NCT01496313 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 81 participants.
The verdict
NCT01496313, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
Study Summary
The purpose of this study is to give patients with medullary thyroid cancer either 300mg/day or 150mg/day vandetanib and compare how well each dose affects how their cancer responds. It will also help the investigators understand the side effects of different doses in these patients.
Interventions
- DRUG 300mg vandetanib
- DRUG 150mg vandetanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2012-06-08 |
| Est. Completion | 2024-07-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01496313
The ClinicalTrials.gov registry entry for NCT01496313 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 300mg vandetanib is the first listed.
NCT01496313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01496313 about?
NCT01496313 is a clinical study titled "To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer". The purpose of this study is to give patients with medullary thyroid cancer either 300mg/day or 150mg/day vandetanib and compare how well each dose affects how their cancer responds. It will also help the investigators understand the side effects of different doses in these patients.
What is the current status of trial NCT01496313?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2012-06-08. Estimated completion is 2024-07-11.
What interventions are being tested in trial NCT01496313?
The interventions under investigation include: 300mg vandetanib (DRUG), 150mg vandetanib (DRUG).
Who is sponsoring clinical trial NCT01496313?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.